Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus

BACKGROUND: The sodium-dependent glucose co-transporter-2 (SGLT2) is expressed in absorptive epithelia of the renal tubules. Remogliflozin etabonate (RE) is the prodrug of remogliflozin, the active entity that inhibits SGLT2. An inhibitor of this pathway would enhance urinary glucose excretion (UGE)...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Hussey, Elizabeth K, Kapur, Anita, O’Connor-Semmes, Robin, Tao, Wenli, Rafferty, Bryan, Polli, Joseph W, James, Charles D, Dobbins, Robert L
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2013
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3682882/
https://ncbi.nlm.nih.gov/pubmed/23631443
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2050-6511-14-25
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki